REVAMP Act

Summary

Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a "priority antimicrobial product." (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 28 June 2018

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 28 June 2018

   Introduced

   Introduced in House

   Source: IntroReferral

3. 28 June 2018

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 28 June 2018 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 28 June 2018

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 28 June 2018

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 28 June 2018

  Open at official source

Sponsors

• JOHN SHIMKUS · R · Sponsor
• Tony Cárdenas · D · Sponsor
• Anna Eshoo · D · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.